ferritin heavy chain 1 pseudogene 27Genealiases: []
Q-omics provides the consensus-scored FTH1P27 profile across patient tissues and cancer cell-line models. FTH1P27 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FTH1P27 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, FTH1P27 RNA expression shows 4,699 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight MESO, HNSC, and SKCM as cancer lineages where FTH1P27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTH1P27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTH1P27 survival associations across molecular data types. FTH1P27 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTH1P27 RNA expression–survival associations across cancer types. High FTH1P27 expression shows unfavorable associations in MESO, LUSC, BRCA, THCA, THYM and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FTH1P27 RNA expression.
This table summarizes FTH1P27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FTH1P27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTH1P27 shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, THCA and COAD. The HNSC box plot shows higher FTH1P27 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p = .003).
This table shows molecular features associated with FTH1P27 in patient tissues and cancer cell lines. In patient samples, FTH1P27 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
